Markus Wenk’s current research is determination of natural variation of circulating metabolites beyond well-known examples such as cholesterol. This knowledge will form a conceptual basis for integration of molecular phenotyping into precision health and medicine. In that context he and his team has initiated and are currently coordinating global trials aimed at technology harmonization and determination of biological reference ranges. Markus Wenk is a thought leader in mass spectrometry based lipidomics. He established the Singapore lipidomics incubator (SLING) and more recently the ‘NUS-Agilent Hub for translation and capture’, a $28 million facility for translation of biochemical innovation and techniques to clinical testing.
Clinical & Research Tools Showcase:
National University of Singapore
A public private partnership and Singapore’s first integrated translational R&D hub that leverages on biochemical innovation and data analytics to develop new methods for translation of clinical research into diagnostics and precision medicine.
Partnership Hub for Clinical Translation of Technology
I will introduce our partnership model from academic R&D laboratories with downstream reach to hospital-based laboratory medicine. Examples of biological variation of circulating blood metabolites will be provided together with its relevance for data-driven trials and clinical implementation.